An observational study in Hip Osteoarthritis and Knee Osteoarthritis, sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-11.
Sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies in Osteoarthritis, Hip with a site in Canada — 9 open to participants now, 13 under way, none of them phase 3. Osteoarthritis, Hip · Canada.
Among the 49 studies in Osteoarthritis, Hip with a site in Canada, this one is one of 7 that started in 2023, is one of 8 observational ones, reaches primary completion later than 1 of the 12 other live ones, and was the 36th registered.
642 studies on the registry are indexed under Osteoarthritis, Hip; 120 are open to participants now.
Browse Osteoarthritis, Hip studies →9 of the 49 studies in Osteoarthritis, Hip with a site in Canada are open now. Recruiting first, the newest first:
University Health Network, Toronto · Sites in Canada
Ages 40–80
University of British Columbia · Sites in Canada
Ages 50+
University of Alberta · Sites in Canada
Canadian Radiostereometric Analysis Network · Sites in Canada
Ages 21+ · Healthy volunteers
Ottawa Hospital Research Institute · Sites in Canada
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 86 Osteoarthritis, Hip studies recruiting now, 53 (62%) set no upper age limit and 7 (8%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 5 · Phase 4 2
First in 2004; this study’s year is marked. 7 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3,008 is above the median of 135 across 158 observational studies indexed under Osteoarthritis, Hip.
Median enrollment 96 across the 41 interventional studies, 70 across the 8 observational. Of the 30 that completed or were terminated, 8 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 49 have an industry lead sponsor. The 10 most frequent:
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's is the lead sponsor of 332 studies on the registry; 137 are open to participants now.
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's has 3 studies filed under Osteoarthritis, Hip — fewer than ten, so there is no comparison to draw.
4 of the studies in Osteoarthritis, Hip with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06878417University Health Network, TorontoCannabinoids for Osteoarthritis Pain Effectiveness Trial | 2026-12-31 |
| NCT03372278Zimmer BiometPMCF Study on the Safety and Performance of the Zimmer® Maxera™ Acetabular System in Total Hip Arthroplasty | 2027-01 |
| NCT05543941Ottawa Hospital Research InstituteEvaluating XPERIENCE™ Advanced Surgical Irrigation | 2027-03-31 |
| NCT06173713Canadian Radiostereometric Analysis NetworkEmphasys Radiostereometric Analysis | 2027-08-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 49 studies in Osteoarthritis, Hip with a site in Canada, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Total hip and knee replacements (TJR) for osteoarthritis are common orthopaedic procedures performed in Canada. Waits for these procedures are already common and lengthy, and the COVID-19 pandemic has resulted in the further of delay of thousands of scheduled TJRs. Longer wait times for TJR can be associated with increased pain and functional disability, and up to 80% of patients awaiting TJR use opioids for pain management. Further, pre-operative pain, functional disability and opioid use has been linked to worse recovery and continued opioid abuse post-operatively. Interestingly, some clinical studies have shown that not all patients experience a deterioration in symptoms while on the waitlist for TJR, and a longer wait time is not always associated with poor post-operative outcomes. However, there is insufficient evidence surrounding the relationships between wait time, patient characteristics, and outcomes both prior to and following hip or knee replacement.
The Investigators aim to establish a large prospective cohort of patients with osteoarthritis waiting for TJR with key research questions and the overarching objectives of identifying which patients deteriorate while on the waitlist, and how wait time affects patient-important outcomes following surgery.
The study will enroll 3008 patients awaiting TJR at 10 Centres from across Canada. All participating site investigators are fellowship trained Orthopaedic surgeons, working in acute care facilities with active research programs and dedicated research staff. The study will follow the patients from their waitlist enrolment up to two years post-operatively. During this time, the research team will collect pain, function, opioid use, and quality of life measures at regular intervals. In addition, an economic analysis will be conducted to determine the impact of length of time on a waitlist on patient and healthcare system costs. The data will highlight the consequences of long waits for patients undergoing TJR, information that will improve patient care and provide insight for refining wait list policies.
Understanding the association between sex, gender, SED (socioeconomic deprivation) PD (psychological distress), and the use of NSIs (non- surgical interventions) with distinct trajectories of deterioration prior to TJR, and the interactions between these variables, wait time, and post-operative recovery could help identify patient groups with the greatest unmet needs, and develop appropriate care plans. Effective waitlist management requires tracking the flow of patients as they progress toward surgery to identify patients at high or low risk of deterioration. Identifying those who require enhanced support while awaiting TJR, as well as delineating the relationship between wait time and post-operative outcomes within trajectory subgroups will enable targeted, patient-centered care. Managing waitlists for TJR based on evidence-based, clinically informative subgroups could eliminate inefficiencies and inequities in decision making and smooth the flow of patients. For these reasons, we aim to establish WHERE, the first prospective longitudinal study of patients awaiting TJR with the overarching objective of identifying which patients are most affected by longer waits, and how inequities affect the progression of symptoms prior-to, and recovery following TJR.
Managing waitlists for TJR based on evidence-based, clinically informative subgroups could eliminate inefficiencies and inconsistencies in decision making and smooth the flow of patients. For these reasons, the Investigators aim to establish WHERE, the first prospective cohort study of patients awaiting TJR with targeted research questions, and the overarching objective of identifying which patients deteriorate while on the waitlist and which patients may tolerate longer wait times.
WHERE will be the first prospective study to investigate distinct group-based trajectories of pre-operative pain, functional ability, opioid use, and health resource utilization (HRU) and their association with TJR patient characteristics and post-operative recovery and outcomes. The data collected will outline complex associations between delivery of care and symptoms in a representative setting, identify where performance improvement efforts need to be targeted, allow better identification and treatment of high-risk subgroups, and help set the foundation for creating improved, risk-stratified care pathways.
We have identified the following research questions as priorities to address with the WHERE cohort:
What factors are associated with different trajectories of preoperative symptoms and opioid use in patients awaiting TJR?
There is a paucity of evidence surrounding the trajectory of pre-operative symptoms and functional ability in patients with end-stage OA awaiting TJR, and how these may differ by SED or psychological variables.
Study Aims:
i) Determine whether previously identified trajectories of OA symptom progression are reproducible in patients scheduled for TJR in Canada; ii) Describe the relationships between SED and psychological variables with trajectory membership; iii) Identify time points in each sub-group where trajectories significantly change.
Could targeted NSIs improve symptom management for patients waiting for TJR? Some patients awaiting TJR may not experience a significant deterioration in symptoms, and as many as 50% of patients undergoing TJR may not be appropriate surgical candidates, suggesting they could benefit from further NSIs prior to being scheduled for TJR.
Study Aims:
i) Characterize variation in the use of NSIs prior to TJR; ii) Identify which NSI types alleviate symptoms while awaiting TJR to inform symptom management programs; iii) Determine whether sex, gender, SED, or PD are associated with the use of, barriers to, and satisfaction with NSIs.
Is the association between wait time and postoperative outcomes modified by trajectory group? Differences in the progression of symptoms while awaiting TJR may contribute to the inconsistent evidence surrounding the relationship between wait time and postoperative outcomes.
Study Aims:
i) Determine how longer wait times impact post-TJR outcomes in different trajectory groups; ii) Identify wait time thresholds within sub-groups to establish evidence-based targets.
Study Aims:
i) Provide insight into the association between variable pre-operative symptom trajectories and health-care system costs; ii) Examine the association between patient-centered wait time thresholds within trajectory sub-groups and health-care system costs following TJR.
All patients with hip or knee OA booked for a surgical consult at the participating sites will be eligible for inclusion based on the above inclusion/exclusion criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This study is observational in nature and does not involve any experimental treatments or additional radiographs, diagnostic tests or clinical interventions beyond what is regularly prescribed within the context of standard of care for each patient. Outcomes for participants will be measured and captured primarily during regularly scheduled clinic/hospital visits, which include standard of care clinical examinations. Participants will be asked to complete study questionnaires as per the visit schedule and participant data will be recorded on applicable study CRFs at the appropriate time points. CRFs detailing patient, injury, and treatment variables of interested will be collected at the time of recruitment.
Patient-reported pain and functional ability
Patient-reported pain and functional ability, measured by the Hip/Knee Disability and Osteoarthritis, Joint Replacement scores (H/KOOS-JR).The H/KOOS-JR scores were developed specifically for patients with OA undergoing TJR, and have sufficient measurement properties in OA patients undergoing TJR when administered in person or via telephone.
Time frame: 24 months
Prescription opioid use
Measured via the Narcotics Monitoring System
Time frame: 24 months
Perceived disability
Measured via the Pain Disability Questionnaire.
Time frame: 24 months
Social support
Measured via the modified Medical Outcomes Study-Social Support Scale (MOS-SSS).
Time frame: 24 months
Health-related quality of life (HRQOL)
Measured using the patient-reported EuroQol-5D-5L (EQ5D) score.
Time frame: 24 months
Physical Activity
Measured via the International Physical Activity Questionnaire short form.
Time frame: 24 months
Health Services Utilization (HSU) and costs
Measured using the patient-reported Ambulatory and Home Care Record (AHCR), which assesses the total cost of illness from a societal perspective, and has very high agreement with administrative HSU. In addition, we will obtain administrative HSU and cost data from the databases at the Institute for Clinical Evaluative Sciences (ICES). Costs will include all costs incurred to the Ministry of Health and Long-Term Care (MoHLTC).
Time frame: 24 months
Behavioral Pain
Collected via the Chronic Pain Behavioral Pain Scale (CPBPs), an objective pain scale developed to mitigate over-exaggeration in self-reported pain
Time frame: 12 and 24 months
Patient global assessment of health
Collected via a validated Visual Analog Scale (0 = very poor health).
Time frame: 12 and 24 months
Patient Satisfaction
Via a valid and reliable patient-reported measure that evaluates patients' satisfaction with their TJR. This measure considers pain relief, ability to do house/yard work or recreational activities, as well as overall satisfaction and how TJR improved their quality of life.
Time frame: 12 and 24 months
Clinical outcomes (Radiographic and Performance).
Measured and recorded by a trained, independent assessor where possible, including: * Radiographic: Radiolucencies, wear and osteolysis, component loosening, instability, or heterotopic ossification. * Performance: The OMERACT-OARSI recommended timed up and go test (TUG), which valid and reliable for patients with hip and knee OA
Time frame: 12 and 24 months
Complications
Including those detected radiographically (listed above), infection, leg length discrepancy, instability and dislocation, peri-prosthetic fracture, or any re-operations.
Time frame: As needed.
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2023 (actual). Primary completion is estimated for Dec 2025, 29 months after the start.
Of 52 non-industry observational studies under Osteoarthritis, Hip, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 59. This study's planned 29 months is above that.
Counting every sponsor, half of 81 studies reached it within 53 months; a quarter within 13 and three quarters within 113.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's →